Jubilant Pharmova Q1 FY27 Results: Consolidated Profit Declines to ₹564 Crore
Jubilant Pharmova reported unaudited consolidated results for Q1 FY27. Revenue from operations was ₹22,294 crore and profit after tax was ₹564 crore. Standalone revenue was ₹671 crore with a profit of ₹73 crore. The results were approved by the Board on August 10, 2026.
The decline in both consolidated and standalone profits, while significant, is a quarterly result. The impact on the stock price will depend on market reaction and any further guidance provided by the company. However, the negative trend warrants a medium impact assessment.
The consolidated profit after tax for the quarter ended June 30, 2026, at ₹564 crore, shows a significant decrease compared to the ₹1,025 crore reported for the same quarter in the previous fiscal year (June 30, 2025). The standalone profit also saw a substantial drop from ₹572 crore to ₹73 crore.
Jubilant Pharmova Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company's Board of Directors approved these results at a meeting held on August 10, 2026.
For the quarter ended June 30, 2026, the consolidated revenue from operations stood at ₹22,294 crore. The consolidated profit after tax was ₹564 crore. This represents a decline compared to the same period in the previous year.
The company also reported standalone financial results for the quarter. Standalone revenue from operations was ₹671 crore, with a profit after tax of ₹73 crore for the quarter ended June 30, 2026.
The financial results, including the limited review report, have been filed with the stock exchanges and will be available on the company's website. The results were reviewed by the Audit Committee and approved by the Board of Directors.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.